Skip to main content
MACROGENICS INC logo

MACROGENICS INC — Investor Relations & Filings

Ticker · MGNX ISIN · US5560991094 LEI · 5493001KJQUA83L8MH79 US Manufacturing
Open in API
Filings indexed 894 across all filing types
Latest filing 2015-05-21 Director's Dealing
Country US United States of America
Listing US MGNX

About MACROGENICS INC

https://www.macrogenics.com/

MacroGenics, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative antibody-based therapeutics for the treatment of cancer. The company utilizes its proprietary antibody engineering platforms, including the DART (Dual-Affinity Re-Targeting) and TRIDENT technologies, to create novel product candidates. Its pipeline consists of investigational treatments such as monoclonal antibodies, antibody-drug conjugates (ADCs), and multi-specific antibodies. MacroGenics maintains fully-integrated capabilities, from research and discovery through to GMP (Good Manufacturing Practice) manufacturing, to advance its portfolio of potential medicines for patients with unmet medical needs.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2015-05-21 English
FORM 4
Director's Dealing
2015-05-18 English
FORM 4
Director's Dealing
2015-05-13 English
Earnings Release 2015
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated May 6, 2015, reporting the company's financial and operating results for the period ended March 31, 2015. It specifically states that the full text of the press release announcing these results is attached as Exhibit 99.1. The document itself is a current report announcing the earnings release, not the earnings release report itself. The length is 2834 characters, which is relatively short and consistent with an announcement rather than a full report. According to the rules, initial announcements of quarterly or periodical financial results (key highlights only) are classified as Earnings Release (ER). Since this is a Form 8-K announcing the earnings results and attaching the press release, it fits the Earnings Release category rather than a full Interim Report or Annual Report. Therefore, the correct classification is ER with high confidence.
2015-05-06 English
FORM 10-Q
Interim / Quarterly Report Q1 2015
2015-05-06 English
FORM 4
Director's Dealing
2015-04-29 English

Browse filings by year

19 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.